Care Creations...

Myoxinol[™] The vegetal answer to smooth expression lines

Beauty Creations

The Passion for Beauty



The vegetal answer to smooth expression lines

Expression lines

There are 2 main mechanisms in wrinkle formation: biological (aging of cells, oxidation or glycation of macromolecules...), and mechanical, when face muscles are involved.

Facial muscles are responsible for the formation of dynamic wrinkles: horizontal and vertical frown lines across the forehead, crow's feet around the eyes and «naso-labial» lines around the mouth.



As long as biological aging mechanisms have not altered the skin's mechanical properties, these lines are reversible and the skin recovers a smooth appearance when facial muscles relax.

But when biological and mechanical factors are combined, the skin loses its elasticity and its ability to return to its initial state, prior to muscle contraction.

The dynamic wrinkles become permanent, generating «expression lines».

A recent advance in the cosmetic dermatology industry, Botox[®] injections, offers to erase these dynamic wrinkles by inhibiting facial muscle contraction.

To answer the need for a topical, gentle alternative to drastic procedures, Beauty Creations have developed Myoxinol[™] LS 9736, with targeted activity against expression lines.

Myoxinol[™] actually goes further, as its efficacy against mechanical parameters of aging is complemented by biological benefits, offering a comprehensive anti-wrinkle approach (patented).

Definition / Composition

Myoxinol[™] LS 9736 is a complex of oligopeptides obtained by biotransformation of native proteins from the seeds of *Hibiscus esculentus L. (okra).*

Hibiscus trees grow mainly in South Asia and Africa. Their seeds are widely used in traditional medicine, but also as a food source due to their high nutritional value.

INCI name

Hydrolyzed Hibiscus Esculentus Extract (and) Dextrin.




Fig. 1 - Co-culture of muscle fibers-neurons

Skin benefits

We have demonstrated the efficacy of oligopeptides from Hibiscus seeds to reduce muscle contraction (*in vitro* demonstration), reducing the formation of expression lines.

This Botox[®]-like* activity is complemented by efficacy against biological aging, helping to preserve optimal skin elasticity.

This comprehensive anti-aging approach is demonstrated by a long term clinical evaluation (topical application).

Cosmetics use

- Facial anti-age.
- Topical answer to smooth expression lines.
- Eliminate or reduce frequency of invasive procedures.

Dosage / Solubility / Mode of incorporation

1. Dose of use: 0.5 to 2%.

2. Solubility: Myoxinol[™] LS 9736 is soluble in water, insoluble in oils and fats.

3. Mode of incorporation: Myoxinol[™] LS 9736 must be dissolved in 3 times its weight of water heated at 45 - 50°C, then incorporated into the cosmetic product below 50°C, during the finishing process or at room temperature for cold processing.

Analytical characteristics

1. Aspect: fine powder, beige to pale yellow, of characteristic odor.

2. Specifications: upon request.

Tolerance Good.

Efficacy Test summaries overleaf.

Storage In its original packaging, at 15 - 25°C.

Efficacy tests

Inhibition of muscle cell contraction, in vitro

Aim

Myoxinol[™] LS 9736 wrinkle reduc-tion potential was assessed by an innovative system comprising a co-culture of muscle cells with neurons, which spontaneously displays rhythmically regulated contractions.

This system mimics the hyperactivity of facial muscles responsible for the formation of expression lines. Myoxinol[™]'s inhibitory effect was evaluated by measuring the frequency of contractions. Carisoprodol, a known muscle relaxant, was used as a benchmark.

Protocol





Fig. 2 - Schema of protocol.

Results



Frequency of contractions (% / control just before treatment)

 $\mbox{Fig. 3}$ - Effect on the frequency of contraction of the innervated muscle cells as a function of the incubation time.

Conclusion

Myoxinol™ LS 9736 has significant efficacy to reduce muscle cell contraction.

This effect is longer lasting than the benchmark, yet completely reversible after 24 hours, providing evidence of the harmlessness of Myoxinol[™] on the long term.

Myoxinol[™] inhibits the mechanical factor responsible for expression lines formation.

Anti-oxidant effect (in vitro)

To complement the efficacy versus mechanical parameters, we have demonstrated Myoxinol[™]'s ability to prevent biological aging via antioxidant properties. Free radicals play a predominant role in aging of both components of human skin: cells and extracellular matrix. The oxidation of the dermal macromolecules of the extracellular matrix results in deterioration of skin's mechanical properties.

Cell protection against free radicals

Aim

Evaluation of the anti-free radical capacity of Myoxinol[™] by a battery of chemical and biochemical tests, *in tubo* and *in vitro*. These tests cover primary radical forms as well as secondary reactive forms of oxygen.

Protocol




Fig. 4 - Principle of the anti-free radical screening: chemical, (enzymatic) biochemical tests and on human fibroblasts in survival *in vitro*.

Results




Fig. 4 - Results of the anti-free radical screening: chemical, biochemical tests and on human fibroblasts in survival *in vitro*.

Conclusion

Myoxinol[™] LS 9736 has shown good anti-free radical activity and has activated the natural defenses (reduced glutathione) of the cells against the deleterious effects of free radicals. Myoxinol[™] prevents oxidative damage, thus protecting skin from biological aging.

Anti-wrinkle activity (cllinical test)

Due to its combined efficacy versus both mechanical and biological factors, Myoxinol[™] LS 9736 displays long term anti-aging properties.

Aim

Demonstration of the anti-wrinkle activity of a cream containing 1% Myoxinol[™] versus placebo.

Protocol

12 healthy female volunteers with expression lines, especially in the crow's foot area. Twice a day treatment of the face for 3 weeks. Double blind, with randomization. Quantitative measurement of wrinkle depth by image analysis.

After 3 weeks of treatment

Results

Before treatment




Fig. 6 - Anti-wrinkle activity of Myoxinol[™], evaluated by image analysis. Illustration on 1 subject (issued shade detected in yellow, proportional to the wrinkle's depth).

Mean index of wrinkles' depth Mean surface of the issued shade (mm²)




Fig. 7 - Study of the anti-wrinkle activity of Myoxinol[™] by image analysis versus placebo. Mean evaluation on 12 volunteers of the index of wrinkles' depth, after 3 weeks of treatment.

Conclusion

Myoxinol[™] LS 9736 has a strong anti-wrinkle capacity, due to its ability to reduce facial muscle contraction via a topical application, combined with a protective efficacy towards oxidative stress.

Due its mechanisms of action, Myoxinol $^{\scriptscriptstyle\rm M}$ LS 9736 particularly targets the prevention and smoothing of expression lines.

EUROPE

BASF Beauty Creations 49, avenue Georges Pompidou 92593 Levallois-Perret Cedex France Tel: +33 (0) 1.49.64.53.97 Fax: +33 (0) 1.49.64.53.85 bcs-europe@basf.com

AMERICAS

Beauty Creations BASF Corporation 50 Health Sciences Drive Stony Brook, NY 11790 USA Tel: +1 (631) 380 2300 Fax: +1 (631) 689 2904 bcs-northamerica@basf.com

JAPAN & ASIA-PACIFIC

 BASF Japan Ltd.

 21F Roppongi Hills Mori Tower,

 6-10-1 Roppongi, Minato-ku,

 Tokyo, 106-6121

 JAPAN

 Tel: +81 (0) 3-3796-9214

 Fax: +81 (0) 3-3796-9299

 bcs-asia@basf.com



The Chemical Company

Edition April 24, 2012

Although all statements and information in this publication are believed to be accurate and reliable, they are presented gratis and for guidance only, and risks and liability for results obtained by use of the products or application of the suggestions described are assumed by the user. THERE ARE NO WARRANTIES OF ANY KIND. ALL EXPRESS AND IMPLIED WARRANTIES ARE DISCLAIMED. Statements or suggestions concerning possible use of the products are made without representation or warranty that any such use is free of patent infringement and are not recommendations to infringe any patent. The user should not assume that toxicity data and safety measures are indicated or that other measures may not be required. The claims and supporting data provided in this publication have not been evaluated for compliance with any jurisdiction's regulatory requirements and the results reported may not be generally true under other conditions or in other matrices. Users must evaluate what claims and information are appropriate and comply with a jurisdiction's regulatory requirements. Recipient of this publication agrees to (i) indemnify and hold harmless each entity of the BASF organization for any and all regulatory action arising from recipient's use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and (ii) not present this publication as evidence of finished product claim substantiation to any regulatory authority.